# A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)

> **NCT02109874** · PHASE1 · COMPLETED · sponsor: **Aeras** · enrollment: 40 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** AERAS-404 (mcg H4/nmol IC31)
- **BIOLOGICAL:** Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl

## Key facts

- **NCT ID:** NCT02109874
- **Lead sponsor:** Aeras
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-12
- **Final completion:** 2012-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109874, "A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02109874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*